Patents by Inventor Nicholas J. Viney
Nicholas J. Viney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230149438Abstract: Provided herein are methods of administering ISIS 721744 for ameliorating edema, and methods of reducing prekallikrein (PKK) RNA, protein or activity in a human subject in need thereof. In certain instances, methods are useful for ameliorating at least one symptom of hereditary angioedema. Such symptoms of hereditary angioedema include, but are not limited to, nausea, vomiting, itching, headache, fatigue, abdominal pain, shortness of breath, rhinitis, anaphylaxis, bronchoconstriction, and swelling. In certain instances, methods are useful for ameliorating at least one symptom of macular edema. Such symptoms of macular edema include, but are not limited to, impaired vision and vision loss.Type: ApplicationFiled: March 12, 2021Publication date: May 18, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Eugene Schneider, Nicholas J. Viney, Veronica J. Alexandra, Laura Bordone, Kenneth Newman
-
Publication number: 20220213472Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia, FCS, LPLD, in a patient. Further provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease or metabolic disorder, or a symptom thereof.Type: ApplicationFiled: July 9, 2021Publication date: July 7, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Veronica J. Alexander, Nicholas J. Viney, Joseph L. Witztum
-
Patent number: 11319536Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a). In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.Type: GrantFiled: December 30, 2019Date of Patent: May 3, 2022Assignee: Ionis Pharmacueticals, Inc.Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu
-
Publication number: 20210169917Abstract: Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human.Type: ApplicationFiled: July 28, 2020Publication date: June 10, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu, Rudy Gunawan
-
Publication number: 20200362340Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions.Type: ApplicationFiled: December 30, 2019Publication date: November 19, 2020Applicant: Ionis Pharmaceuticals, Inc.Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu
-
Patent number: 10557137Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.Type: GrantFiled: November 7, 2016Date of Patent: February 11, 2020Assignee: Ionis Pharmaceuticals, Inc.Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu
-
Publication number: 20200017854Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia, FCS, LPLD, in a patient. Further provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease or metabolic disorder, or a symptom thereof.Type: ApplicationFiled: February 25, 2019Publication date: January 16, 2020Applicant: Ionis Pharmaceuticals, Inc.Inventors: Veronica J. Alexander, Nicholas J. Viney, Joseph L. Witztum
-
Publication number: 20190136233Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.Type: ApplicationFiled: November 7, 2016Publication date: May 9, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu, Rudy Gunawan
-
Publication number: 20190046555Abstract: Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human.Type: ApplicationFiled: November 7, 2016Publication date: February 14, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu, Rudy Gunawan
-
Publication number: 20170233732Abstract: Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia, FCS, LPLD, in a patient. Further provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in a patient with Fredrickson Type I dyslipidemia, FCS, LPLD. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease or metabolic disorder, or a symptom thereof.Type: ApplicationFiled: January 25, 2017Publication date: August 17, 2017Applicant: Ionis Pharmaceuticals, Inc.Inventors: Veronica J. Alexander, Nicholas J. Viney, Joseph L. Witztum
-
Patent number: 9593333Abstract: Provided are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia/FCS/LPLD, in a patient. Such methods, compounds, and compositions increase HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in the patient, and are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease, metabolic disorder, and associated symptoms.Type: GrantFiled: February 14, 2014Date of Patent: March 14, 2017Assignee: Ionis Pharmaceuticals, Inc.Inventors: Veronica J. Alexander, Nicholas J. Viney, Joseph L. Witztum
-
Publication number: 20150376614Abstract: Provided are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein for treating, preventing, delaying, or ameliorating Fredrickson Type I dyslipidemia/FCS/LPLD, in a patient. Such methods, compounds, and compositions increase HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in the patient, and are useful to treat, prevent, delay, or ameliorate any one or more of pancreatitis, cardiovascular disease, metabolic disorder, and associated symptoms.Type: ApplicationFiled: February 14, 2014Publication date: December 31, 2015Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Veronica J. Alexander, Nicholas J. Viney, Joseph L. Witztum